PMC full text:
Published online 2024 Jun 10. doi: 10.1186/s12916-024-03462-4
Table 3
Adverse events | Any grade No. (%) | Grades 3–4 No. (%) |
---|---|---|
Hematologic adverse events | ||
Neutropenia | 28 (80) | 3 (8.6) |
Anemia | 19 (54.3) | 0 |
Thrombocytopenia | 16 (45.7) | 0 |
Nonhematologic adverse events | ||
Alopecia | 25 (71.4) | 0 |
Fatigue | 6 (17.1) | 0 |
Anorexia | 5 (14.3) | 0 |
Myalgia | 5 (14.3) | 0 |
Paresthesia | 4 (11.4) | 0 |
Nausea | 3 (8.6) | 0 |
Rash | 3 (8.6) | 0 |
Constipation | 2 (5.7) | 0 |
Increased AST | 2 (5.7) | 1 (2.9) |
Increased ALT | 2 (5.7) | 1 (2.9) |
Increased blood creatinine | 1 (2.9) | 0 |
Increased bilirubin | 1 (2.9) | 0 |
AST aspartate transaminase, ALT alanine transaminase